DE69322077T2 - Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe - Google Patents

Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe

Info

Publication number
DE69322077T2
DE69322077T2 DE69322077T DE69322077T DE69322077T2 DE 69322077 T2 DE69322077 T2 DE 69322077T2 DE 69322077 T DE69322077 T DE 69322077T DE 69322077 T DE69322077 T DE 69322077T DE 69322077 T2 DE69322077 T2 DE 69322077T2
Authority
DE
Germany
Prior art keywords
particles
drug
active substances
hydroxyethyl cellulose
oral pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69322077T
Other languages
English (en)
Other versions
DE69322077D1 (de
Inventor
John Shell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assertio Therapeutics Inc
Original Assignee
Depomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Depomed Inc filed Critical Depomed Inc
Application granted granted Critical
Publication of DE69322077D1 publication Critical patent/DE69322077D1/de
Publication of DE69322077T2 publication Critical patent/DE69322077T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
DE69322077T 1992-03-25 1993-03-17 Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe Expired - Fee Related DE69322077T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85832092A 1992-03-25 1992-03-25
US98695292A 1992-12-08 1992-12-08
PCT/US1993/002420 WO1993018755A1 (en) 1992-03-25 1993-03-17 Alkyl-substituted cellulose-based sustained-release oral drug dosage forms

Publications (2)

Publication Number Publication Date
DE69322077D1 DE69322077D1 (de) 1998-12-17
DE69322077T2 true DE69322077T2 (de) 1999-04-08

Family

ID=27127455

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69322077T Expired - Fee Related DE69322077T2 (de) 1992-03-25 1993-03-17 Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe

Country Status (9)

Country Link
EP (1) EP0632720B1 (de)
JP (2) JPH07507059A (de)
AT (1) ATE173159T1 (de)
AU (1) AU668386B2 (de)
CA (1) CA2132012C (de)
DE (1) DE69322077T2 (de)
DK (1) DK0632720T3 (de)
ES (1) ES2124303T3 (de)
WO (1) WO1993018755A1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993860A (en) * 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
US5549911A (en) * 1994-01-14 1996-08-27 Laboratoires Des Produits Ethiques Ethypharm Galenic form of 5-nitromidazole derivatives which is effective for the treatment of parasitoses and infections of the entire gastrointestinal tract
US5399356A (en) * 1994-03-24 1995-03-21 The Procter & Gamble Company Process for making solid dose forms containing bismuth
WO1995025521A1 (en) * 1994-03-24 1995-09-28 The Procter & Gamble Company Solid dose forms containing bismuth
NZ287277A (en) * 1994-05-13 1998-05-27 Smithkline Beecham Corp Oral preparation containing calcium source within a hydrophilic polymer matrix for increasing calcium absorption in the stomach
ZA959221B (en) 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
AU6403196A (en) 1995-06-30 1997-02-05 Baylor University Polyester/carboxylic acid composite materials
AU3290397A (en) * 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
IL133080A0 (en) 1997-07-01 2001-03-19 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
EA003101B1 (ru) 1998-03-19 2002-12-26 Бристол-Майерз Сквибб Компани Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы
DE19934610A1 (de) 1999-07-23 2001-01-25 Bayer Ag Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
IT1313590B1 (it) * 1999-08-03 2002-09-09 Formenti Farmaceutici Spa Composizioni a rilascio controllato di acido acetilsalicilico.
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
ATE552348T1 (de) 2000-10-19 2012-04-15 Target Discovery Inc Massendefektetikettierung zur bestimmung von oligomersequenzen
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
EP2286817A3 (de) 2003-01-13 2011-06-15 Edusa Pharmaceuticals, Inc Verfahren zur Behandlung von funktionalen Darmerkrankungen
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
US7919483B2 (en) 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US7541347B2 (en) 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7544373B2 (en) 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
CA2614885C (en) 2005-07-11 2015-03-17 Pharmena North America Inc. Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
US8778395B2 (en) 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2010017310A1 (en) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
EA201101524A1 (ru) 2009-04-20 2012-07-30 Элселикс Терапьютикс, Инк. Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
JP2012526133A (ja) 2009-05-05 2012-10-25 ベイポジェニックス インコーポレイテッド 炎症を低減させるための新規揮発性麻酔薬製剤およびその使用法
EP2603215A4 (de) 2010-08-11 2015-08-05 Philadelphia Health & Educatio Neue d3-dopamin-rezeptoragonisten zur behandlung von dyskinesien bei morbus parkinson
WO2012054523A2 (en) 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
JP6076913B2 (ja) 2010-12-07 2017-02-08 ドレクセル ユニバーシティ 癌からの転移を阻害する方法
JP2014501787A (ja) 2011-01-07 2014-01-23 エルセリクス セラピューティクス インコーポレイテッド 化学感覚受容体リガンドに基づく治療法
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
EP2601947A1 (de) * 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Kombinationspräparat mit fester Dosierung zur Behandlung von Erkrankungen einhergehend mit Helicobacter pylori
ES2649410T3 (es) 2011-12-21 2018-01-11 Novira Therapeutics Inc. Agentes antivirales para la hepatitis B
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CA2879454A1 (en) 2012-07-19 2014-01-23 Drexel University Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
WO2014026013A2 (en) 2012-08-09 2014-02-13 Dynamis Therapeutics, Inc. Methods for maintaining or improving health, well-being and/or a physiological function in a subject
CA2896966C (en) 2013-01-07 2021-03-30 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
CA2917149C (en) 2013-07-02 2021-02-02 Cineole Corp., Llc Antimicrobial formulation comprising isoamyl hexanoates together with propanoic acid and/or isobutyric acid
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US9908915B2 (en) 2013-11-26 2018-03-06 Yale University Cell-penetrating compositions and methods using same
US10258615B2 (en) 2013-12-09 2019-04-16 Thomas Jefferson University Methods of treating a neurodegenerative disease in a mammal in need thereof
EP3128996B1 (de) 2014-04-07 2021-06-02 University of Rochester Neuartige 7-dehydrocholesterinderivate und verfahren damit
CN106714809A (zh) 2014-08-20 2017-05-24 耶鲁大学 对治疗或预防肝脏疾病或障碍和促进体重减轻有用的新型组合物和方法
US10597368B2 (en) 2015-05-08 2020-03-24 Brown University Syringolin analogues and methods of making and using same
KR20180005249A (ko) 2015-05-19 2018-01-15 예일 유니버시티 병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법
US10829440B2 (en) 2015-06-12 2020-11-10 Brown University Antibacterial compounds and methods of making and using same
JP6731427B2 (ja) 2015-06-30 2020-07-29 ネウラッド リミテッドＮｅｕｒａｄ Ｌｔｄ． 新規の呼吸制御調節化合物、およびこれを製造し、かつ使用する方法
WO2017075145A1 (en) 2015-10-28 2017-05-04 Yale University Quinoline amides and methods of using same
JP2018537093A (ja) 2015-11-20 2018-12-20 イエール ユニバーシティ 異所性石灰化障害を治療するための組成物およびそれを使用する方法
US20190119364A1 (en) 2016-04-29 2019-04-25 The Regents Of The University Of Colorado, A Body Corporate Compounds and compositions useful for treating metabolic syndrome, and methods using same
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20210330599A1 (en) 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
US11390859B2 (en) 2016-08-05 2022-07-19 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
AU2017321791B2 (en) 2016-09-01 2022-03-24 Mebias Discovery, Inc. Substituted ureas and methods of making and using same
KR102522060B1 (ko) 2016-11-07 2023-04-14 아뷰터스 바이오파마 코포레이션 치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법
EP4219486A1 (de) 2017-01-19 2023-08-02 Temple University of the Commonwealth System of Higher Education Verbrückte bicycloalkyl-substituierte aminothizole und verfahren zu ihrer verwendung
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
US11166953B2 (en) 2017-04-17 2021-11-09 Yale University Compounds, compositions and methods of treating or preventing acute lung injury
WO2019023621A1 (en) 2017-07-28 2019-01-31 Yale University ANTICANCER DRUGS AND METHODS OF MAKING AND USING THEM
US20200323895A1 (en) 2017-11-27 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Compounds, Compositions, and Methods for Treating And/Or Preventing Periodontal Disease
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
AU2019212241A1 (en) 2018-01-24 2020-08-13 The Rockefeller University Antibacterial compounds, compositions thereof, and methods using same
MX2020012805A (es) 2018-05-29 2021-02-15 Cersci Therapeutics Inc Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.
CA3113377A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
KR20210148078A (ko) 2019-01-30 2021-12-07 사니핏 테라퓨틱스 에스.에이. 조직 관류 증가에 사용하기 위한 이노시톨 포스페이트 화합물
US20200246317A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
US20200246316A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
CA3139109A1 (en) 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Hmgb1 antagonist
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
EP3818983A1 (de) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol-phosphat-verbindungen zur verwendung in der behandlung, progressionshemmung oder verhinderung von kardiovaskulärer verkalkung
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
EP4162036A1 (de) 2020-06-09 2023-04-12 Inozyme Pharma, Inc. Lösliche enpp1- oder enpp3-proteine und verwendungen davon
EP4015494A1 (de) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Verfahren zur herstellung von löslichen salzen von inositolphosphaten
EP4036097A1 (de) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6-substituierte derivatverbindungen
WO2024023360A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip5 substituted compounds
WO2024023359A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2024052895A1 (en) 2022-09-06 2024-03-14 Hadasit Medical Research Services And Development Ltd Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
HU179474B (en) * 1978-02-24 1982-10-28 Laszlo Gyarmati Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
IT1250483B (it) * 1990-08-30 1995-04-07 Eurand Int Sistema di ritardo a matrice multipla
DE9107805U1 (de) * 1991-02-22 1991-09-05 Sopar S.A. Division Pharma, Sart Dame Avelines, Be

Also Published As

Publication number Publication date
AU3811493A (en) 1993-10-21
ATE173159T1 (de) 1998-11-15
CA2132012C (en) 2003-04-22
EP0632720A1 (de) 1995-01-11
EP0632720B1 (de) 1998-11-11
DE69322077D1 (de) 1998-12-17
AU668386B2 (en) 1996-05-02
WO1993018755A1 (en) 1993-09-30
DK0632720T3 (da) 1999-07-26
CA2132012A1 (en) 1993-09-30
JP2004203897A (ja) 2004-07-22
JPH07507059A (ja) 1995-08-03
ES2124303T3 (es) 1999-02-01

Similar Documents

Publication Publication Date Title
DE69322077D1 (de) Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
FI914765A0 (fi) Foerdroejt frigoerande oral medicindosform.
US3488418A (en) Sustained relief analgesic composition
ES2213836T3 (es) Formas galenicas orales retenidas en el estomago, para la liberacion controlada de medicamentos debilmente solubles y de sustancia insoluble.
ES2173891T3 (es) Sistema de liberacion pulsatil de un farmaco multiparticulado.
ES2279573T3 (es) Terapia para el estreñimiento.
DE69728710D1 (de) Eine pharmazeutische Tablette charakterisiert durch hohen Volumenzuwachs bei Kontakt mit biologischen Flüssigkeiten
KR880013586A (ko) 고체상태성질을 가진 제거 가능한 기질을 포함하는 투약기
RU97115570A (ru) Применение неорганических аэрогелей в фармации
KR890001598A (ko) 유익한 약제를 투여하는 투약부재가 있는 투약기
KR870010866A (ko) 펄프(pulse)식 약제 전달용 투약형상체
ATE235235T1 (de) Arzneistoffverabreichungssystem auf basis von flüssigkristall-strukturen
Vasave A REVIEW ON: FLOATING DRUG DELIVERY SYSTEM
GB1432784A (en) Orally administrable pharmaceutical compositions
Gidwani et al. Factorial design and a practical approach for gastro-retentive drug delivery system
US6663896B1 (en) Delayed release aspirin for vascular obstruction prophylaxis
Janhavi et al. A Comprehensive Review on Gastro-Retentive Floating Drug Delivery Systems
CN101296687A (zh) 用于系统性药物的口服载体
Rubens et al. Difenoxine (R 15403), the active metabolite of diphenoxylate (R 1132). 5. Clinical comparison of difenoxine and diphenoxylate in volunteers and in patients with chronic diarrhea. Double-blind cross-over assessments
US20200155466A1 (en) Oral Medicine Delivery Capsule
Ravichandiran et al. Chrono pharmaceutical drug delivery system
Kumar et al. Floating Drug Delivery System: A New Approach
Chinnaraja Formulation Development and In Vitro Evaluation of Gastro Retentive Floating Tablets of Betahistine Hydrochloride
Duncan different regimes are used for treating overdoses of each drug, the manage
TH57760B (th) การลำเลียงยาสู่ลำไส้เล็กและลำไส้ใหญ่โดยใช้แคปซูลชนิด hpmc

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: DEPOMED, INC., FOSTER CITY, CALIF., US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee